Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.

Ustun C, DeRemer DL, Akin C.

Leuk Res. 2011 Sep;35(9):1143-52. doi: 10.1016/j.leukres.2011.05.006. Epub 2011 Jun 8. Review.

PMID:
21641642
2.

Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.

Bougherara H, Georgin-Lavialle S, Damaj G, Launay JM, Lhermitte L, Auclair C, Arock M, Dubreuil P, Hermine O, Poul MA.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):62-9. doi: 10.1016/j.clml.2012.08.004. Epub 2012 Nov 3.

PMID:
23127495
3.

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.

Hadzijusufovic E, Peter B, Rebuzzi L, Baumgartner C, Gleixner KV, Gruze A, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Willmann M, Valent P.

Vet Immunol Immunopathol. 2009 Dec 15;132(2-4):243-50. doi: 10.1016/j.vetimm.2009.05.007. Epub 2009 May 18.

PMID:
19505729
4.

Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.

Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P.

Haematologica. 2007 Nov;92(11):1451-9.

5.

Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.

de Melo Campos P, Machado-Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte AS, Barra FF, Vassalo J, Rogers HJ, Lorand-Metze I, Tiu RV, Costa FF, Olalla Saad ST, Traina F.

Leuk Res. 2014 Oct;38(10):1245-51. doi: 10.1016/j.leukres.2014.07.010. Epub 2014 Aug 1.

6.

Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.

Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL.

Cancer. 2006 Jul 15;107(2):345-51.

7.

[Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].

Sotlar K.

Verh Dtsch Ges Pathol. 2007;91:169-76. German.

PMID:
18314612
8.

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S.

Leuk Res. 2009 Nov;33(11):1481-4. doi: 10.1016/j.leukres.2008.12.020. Epub 2009 Feb 3.

9.

Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.

Ustun C, Corless CL, Savage N, Fiskus W, Manaloor E, Heinrich MC, Lewis G, Ramalingam P, Kepten I, Jillella A, Bhalla K.

Leuk Res. 2009 May;33(5):735-41. doi: 10.1016/j.leukres.2008.09.027. Epub 2008 Nov 4.

PMID:
18986703
10.

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.

Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P.

Blood. 2011 Aug 18;118(7):1885-98. doi: 10.1182/blood-2010-06-289959. Epub 2011 Jun 16.

11.

Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.

Pardanani A.

Am J Hematol. 2011 Apr;86(4):362-71. doi: 10.1002/ajh.21982.

12.

Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).

Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bültmann B, Valent P, Horny HP.

J Pathol. 2010 Apr;220(5):586-95. doi: 10.1002/path.2677.

PMID:
20112369
13.

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.

Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Müllauer L, Agis H, Sillaber C, Valent P.

Blood. 2007 Apr 1;109(7):3031-41.

14.

Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.

De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA.

PLoS One. 2014 May 2;9(5):e96209. doi: 10.1371/journal.pone.0096209. eCollection 2014.

15.

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.

Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P.

Blood. 2006 Jan 15;107(2):752-9. Epub 2005 Sep 27.

16.

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutré SE.

Blood. 2005 Oct 15;106(8):2865-70. Epub 2005 Jun 21.

17.

Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.

Jin Y, Ding K, Wang D, Shen M, Pan J.

Cancer Lett. 2014 Oct 10;353(1):115-23. doi: 10.1016/j.canlet.2014.07.017. Epub 2014 Aug 1.

PMID:
25088577
18.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A.

Blood. 2003 Nov 1;102(9):3093-6. Epub 2003 Jul 3.

19.

Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

Sotlar K, Bache A, Stellmacher F, Bültmann B, Valent P, Horny HP.

J Mol Diagn. 2008 Jan;10(1):58-66. doi: 10.2353/jmoldx.2008.070061. Epub 2007 Dec 28. Erratum in: J Mol Diagn. 2009 May;10(3):276.

20.

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.

Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H.

Clin Cancer Res. 2008 Jun 15;14(12):3906-15. doi: 10.1158/1078-0432.CCR-08-0366.

Supplemental Content

Support Center